Publication: Treatment for hemophilia: recombinant versus plasma-derived coagulationfactors – controversy and debateforever? An ethical medical challenge?
Loading...
Official URL
Full text at PDC
Publication Date
2013-10
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Informa Healthcare
Citations
Exportar
Abstract
With the eradication of infection by HIV and hepatitis C virus that were common just a few years ago, the most concerning adverse effect resulting from the use of both recombinant and plasma-derived products is the appearance of antibodies (inhibitors) to perfused exogenous factors.”
Description
UCM subjects
Unesco subjects
Keywords
Citation
1 Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 379,1447–1456 (2012).
2 Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem. Pharmacol. 82, 91–98 (2011).
3 Hermans C, Brackmann HH, Schinco P, Auerswald G. The case for wider use of recombinant factor III concentrates. Crit. Rev. Oncol.Hematol. 83, 11–20 (2012).
4 Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 14, 671–684 (2008).
5 Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 16, 66–70 (2010).
6 Green D. Factor VIII inhibitors: a 50-year perspective. Haemophilia 17, 831–838 (2011).
7 Gouw SC, van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A.N. Engl. J. Med. 368, 231–239 (2013).
8 Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood 119, 4108–4114 (2012).
9 Tarantino MD, Ye X, Bergstrom F, Skorija K, Luo MP. The impact of the economic downturn and health care reform
on treatment decisions for haemophilia A: patient, caregiver and health care provider perspectives. Haemophilia 19, 51–58 (2013).
10 Skinner MW. Gene therapy for hemophilia: Addressing the coming challenges of Treatment for hemophilia Editorial www.expert-affordability and accessibility. Mol. Ther. 21,1–2 (2013).
11 Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates:
A critical systematic review. Crit. Rev. Oncol. Hematol. 81, 82–93 (2012).
12 Kamar N, Bendall R, Legrand-Abravanel F et al. Hepatitis E. Lancet 379, 2477–2488 (2012).
13 Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis e virus infection.Gastroenterology 142,1388–1397 (2012).
14 Andréoletti O, Litaise C, Simmons H et al.Highly efficient prion transmission by blood transfusion. PLoS Pathog. 8, e1002782 (2012).
15 Zaman SMA, Hill FGH, Palmer B et al. The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially
contaminated plasma products. Haemophilia 17, 931–937 (2011).
16 Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood 120, 720–727 (2012).
17 Arrieta R, Altisent C, A ´ lvarez T et al. Hemophilia: Therapeutic Guidelines (1st Edition). Ministry of Health, Social Services and Equality of Spain, Madrid (2012).
18 De Mendoza C, Altisent C, Aznar JA, Batlle J, Soriano V. Emerging viral infections – a potential threat for blood supply in the 21st century. AIDS Rev. 14, 279–289 (2012).